Liminatus Pharma, Inc. (LIMN)Healthcare | Biotechnology | La Palma, United States | NasdaqGM
0.22 USD
-0.01
(-4.739%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.21 -0.01 (-0.007%) ⇩ (April 17, 2026, 7:57 p.m. EDT) Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:03 a.m. EDT
LIMN is a high-risk speculative vehicle with no long-term investment thesis: it is trading near all-time lows, is fundamentally insolvent (current ratio 0.049, negative book value), has never paid a dividend, and a quantitative forecasting model predicts a -27.7% price decline over the next 45 days due to structural price discovery anomalies. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.699205 |
| MSTL | 0.960663 |
| AutoARIMA | 0.972601 |
| AutoETS | 0.986292 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 48% |
| H-stat | 1.21 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 2.48 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 9,832,689 |
| Beta | 0.63 |
| Previous Name | Liminatus Pharma, LLC |
| Website | https://liminatuspharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9727612 |
| Address1 | 6 Centerpointe Drive |
| Address2 | #625 |
| All Time High | 33.66 |
| All Time Low | 0.159 |
| Ask | 0.234 |
| Ask Size | 6 |
| Average Daily Volume10 Day | 15,752,840 |
| Average Daily Volume3 Month | 11,277,206 |
| Average Volume | 11,277,206 |
| Average Volume10Days | 15,752,840 |
| Beta | 0.628 |
| Bid | 0.212 |
| Bid Size | 1 |
| Book Value | -0.363 |
| City | La Palma |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.2191 |
| Current Ratio | 0.049 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.24 |
| Day Low | 0.2047 |
| Display Name | Liminatus Pharma |
| Ebitda | -2,965,984 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.688 |
| Enterprise Value | 10,937,534 |
| Eps Trailing Twelve Months | -0.43 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.34712 |
| Fifty Day Average Change | -0.12801999 |
| Fifty Day Average Change Percent | -0.36880615 |
| Fifty Two Week Change Percent | -97.27612 |
| Fifty Two Week High | 33.66 |
| Fifty Two Week High Change | -33.4409 |
| Fifty Two Week High Change Percent | -0.99349076 |
| Fifty Two Week Low | 0.159 |
| Fifty Two Week Low Change | 0.060100004 |
| Fifty Two Week Low Change Percent | 0.37798747 |
| Fifty Two Week Range | 0.159 - 33.66 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,746,192,600,000 |
| Float Shares | 29,071,731 |
| Free Cashflow | 7,141,122 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.38489 |
| Held Percent Institutions | 0.0070700003 |
| Implied Shares Outstanding | 44,877,633 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-05-01 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California. |
| Long Name | Liminatus Pharma, Inc. |
| Market | us_market |
| Market Cap | 9,832,689 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_570895157 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -10,206,517 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 9,832,689 |
| Open | 0.2161 |
| Operating Cashflow | -9,963,318 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 213 273 5453 |
| Post Market Change | -0.007100001 |
| Post Market Change Percent | -3.24053 |
| Post Market Price | 0.212 |
| Post Market Time | 1,776,470,269 |
| Prev Name | Liminatus Pharma, LLC |
| Previous Close | 0.23 |
| Price Hint | 4 |
| Price To Book | -0.60358125 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.033 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0109 |
| Regular Market Change Percent | -4.73913 |
| Regular Market Day High | 0.24 |
| Regular Market Day Low | 0.2047 |
| Regular Market Day Range | 0.2047 - 0.24 |
| Regular Market Open | 0.2161 |
| Regular Market Previous Close | 0.23 |
| Regular Market Price | 0.2191 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 3,877,522 |
| Return On Assets | -0.62646997 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 44,877,633 |
| Shares Percent Shares Out | 0.015700001 |
| Shares Short | 705,229 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,307,493 |
| Short Name | Liminatus Pharma, Inc. |
| Short Percent Of Float | 0.0217 |
| Short Ratio | 0.48 |
| Source Interval | 15 |
| State | CA |
| Symbol | LIMN |
| Total Cash | 337,655 |
| Total Cash Per Share | 0.008 |
| Total Debt | 1,442,500 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.43 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.858435 |
| Two Hundred Day Average Change | -1.639335 |
| Two Hundred Day Average Change Percent | -0.8821051 |
| Type Disp | Equity |
| Volume | 3,877,522 |
| Website | https://liminatuspharma.com |
| Zip | 90,623 |